We are live on !
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter Est. Return
+21.1%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
-$150M
(-5%)
Cap. Flow
-$428M
Cap. Flow % of AUM
Cap. Flow %
-14.96%
Top 10 Holdings %
Top 10 Hldgs %
28.09%
Holding
113
New
30
Increased
18
Reduced
43
Closed
20
Avg Time Held
0.7
years
Top 10 Avg Time Held
0.3
years
Top 20 Avg Time Held
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE HealthCare
GEHC
|
+$83.4M |
| 2 |
AbbVie
ABBV
|
+$76M |
| 3 |
Eli Lilly
LLY
|
+$55.8M |
| 4 |
Pfizer
PFE
|
+$43.5M |
| 5 |
Apellis Pharmaceuticals
APLS
|
+$40.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$72.7M |
| 2 |
Surgery Partners
SGRY
|
+$68.7M |
| 3 |
Akero Therapeutics
AKRO
|
+$65.2M |
| 4 |
Merck
MRK
|
+$63.8M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$56.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Technology | 0.02% |
| 3 | Miscellaneous | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
DexCom
DXCM
$32.5B
| – | – |
-148,000
| Closed | -$17.2M | – |
|
102
Geron
GERN
$752M
| – | – |
-2,128,000
| Closed | -$4.62M | – |
|
103
Icon
ICLR
$13.1B
| – | – |
-142,900
| Closed | -$30.5M | – |
|
|
104
Merck
MRK
$360B
| – | – |
-600,000
| Closed | -$63.8M | – |
|
105
Praxis Precision Medicines
PRAX
$6.75B
| – | – |
-285,447
| Closed | -$3.46M | – |
|
|
RNAM
106
DELISTED
Avidity Biosciences
RNAM
| – | – |
-1,265,545
| Closed | -$19.4M | – |
|
107
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| – | – |
-2,470,000
| Closed | -$4.35M | – |
|
108
Twist Bioscience
TWST
$8.8B
| – | – |
-819,000
| Closed | -$12.4M | – |
|
|
KNTE
109
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| – | – |
-1,160,000
| Closed | -$7.25M | – |
|
|
CYT
110
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| – | – |
-1,764,100
| Closed | -$3.21M | – |
|
|
REUN
111
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
| – | – |
-151,098
| Closed | -$104K | – |
|
|
ISEE
112
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-1,869,200
| Closed | -$45.5M | – |
|
|
BLU
113
DELISTED
BELLUS Health Inc.
BLU
| – | – |
-4,553,577
| Closed | -$32.8M | – |
|
Similar funds
BVC
Avidity Partners Management's Q2 2023 Portfolio in Review
As of Q2 2023, Avidity Partners Management held 113 positions worth $2.86B, down 5% from $3.01B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Avidity Partners Management withdrew a net $428M in Q2 2023, closing 20 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $63.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Miscellaneous.
Against the trend, Avidity Partners Management opened a new position in GE HealthCare worth $84.9M.
- Avidity Partners Management's largest Q2 2023 buy was GE HealthCare: 1,045,400 shares worth $84.9M.
- Avidity Partners Management added most to Cencora in Q2 2023, an estimated $30M increase.
- Avidity Partners Management's biggest Q2 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $72.7M.
- Avidity Partners Management fully exited Merck in Q2 2023, selling an estimated $63.8M.
- Avidity Partners Management's ten largest holdings make up 28% of its $2.86B portfolio in Q2 2023.
- Avidity Partners Management opened 30 new positions and closed 20 in Q2 2023.
- Avidity Partners Management's portfolio value fell 5% quarter-over-quarter to $2.86B.
Based on Avidity Partners Management's 13F filing for Q2 2023, filed 14 Aug 2023.